Do analysts rate RZLT or DTSQ?

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 144.14%. Given Rezolute's stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, RZLT or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is RZLT or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% DT Cloud Star Acquisition N/A N/A N/A

Which has higher earnings & valuation, LRMR or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is LRMR or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% DT Cloud Star Acquisition N/A N/A N/A

Do analysts recommend ARCT or DTSQ?

Arcturus Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 43.48%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ARCT or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Arcturus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcturus Therapeutics $18.72M 24.33 -$65.78M -$3.31 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Do analysts prefer DTSQ or EVMN?

Evommune has a consensus target price of $33.33, indicating a potential upside of 245.28%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evommune 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73

Which has higher valuation and earnings, DTSQ or EVMN?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Evommune $10M 35.04 -$68.87M -$11.03 N/A

Is DTSQ or EVMN more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Evommune N/A -62.63% -40.55%

Do analysts rate RCKT or DTSQ?

Rocket Pharmaceuticals currently has a consensus price target of $8.63, indicating a potential upside of 155.93%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 3 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.36 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, RCKT or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is RCKT or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% DT Cloud Star Acquisition N/A N/A N/A

DT Cloud Star Acquisition (DTSQ) Competitors

$11.58 +0.08 (+0.70%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$11.51 -0.07 (-0.64%)

As of 09/18/2026 07:03 PM Eastern

Compare

DTSQ vs. RZLT, LRMR, ARCT, EVMN, and RCKT

Should you buy DT Cloud Star Acquisition stock or one of its competitors? DT Cloud Star Acquisition's main competitors and comparable companies include Rezolute (RZLT), Larimar Therapeutics (LRMR), Arcturus Therapeutics (ARCT), Evommune (EVMN), and Rocket Pharmaceuticals (RCKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DT Cloud Star Acquisition compare to Rezolute?

Rezolute (NASDAQ:RZLT) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Rezolute had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 2 mentions for Rezolute and 0 mentions for DT Cloud Star Acquisition. Rezolute's average media sentiment score of 0.79 beat DT Cloud Star Acquisition's score of 0.00 indicating that Rezolute is being referred to more favorably in the media.

Company	Overall Sentiment
Rezolute	Positive
DT Cloud Star Acquisition	Neutral

DT Cloud Star Acquisition's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
DT Cloud Star Acquisition	N/A	N/A	N/A

Rezolute presently has a consensus target price of $9.38, suggesting a potential upside of 144.14%. Given Rezolute's stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rezolute has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Rezolute beats DT Cloud Star Acquisition on 7 of the 10 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Larimar Therapeutics presently has a consensus target price of $11.86, suggesting a potential upside of 212.85%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Larimar Therapeutics had 3 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 3 mentions for Larimar Therapeutics and 0 mentions for DT Cloud Star Acquisition. Larimar Therapeutics' average media sentiment score of 0.65 beat DT Cloud Star Acquisition's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
DT Cloud Star Acquisition	Neutral

DT Cloud Star Acquisition's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
DT Cloud Star Acquisition	N/A	N/A	N/A

Larimar Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Larimar Therapeutics beats DT Cloud Star Acquisition on 8 of the 11 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Arcturus Therapeutics had 6 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 0 mentions for DT Cloud Star Acquisition. Arcturus Therapeutics' average media sentiment score of 0.53 beat DT Cloud Star Acquisition's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcturus Therapeutics	Positive
DT Cloud Star Acquisition	Neutral

DT Cloud Star Acquisition has lower revenue, but higher earnings than Arcturus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$18.72M	24.33	-$65.78M	-$3.31	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. DT Cloud Star Acquisition's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
DT Cloud Star Acquisition	N/A	N/A	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Arcturus Therapeutics currently has a consensus price target of $23.00, indicating a potential upside of 43.48%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arcturus Therapeutics beats DT Cloud Star Acquisition on 9 of the 13 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Evommune?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

DT Cloud Star Acquisition has higher earnings, but lower revenue than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Evommune	$10M	35.04	-$68.87M	-$11.03	N/A

In the previous week, Evommune had 4 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Evommune and 0 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 0.00 beat Evommune's score of -0.28 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
DT Cloud Star Acquisition	Neutral
Evommune	Neutral

DT Cloud Star Acquisition's return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

Evommune has a consensus target price of $33.33, indicating a potential upside of 245.28%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Evommune beats DT Cloud Star Acquisition on 6 of the 9 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
DT Cloud Star Acquisition	N/A	N/A	N/A

Rocket Pharmaceuticals currently has a consensus price target of $8.63, indicating a potential upside of 155.93%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Rocket Pharmaceuticals had 17 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 17 mentions for Rocket Pharmaceuticals and 0 mentions for DT Cloud Star Acquisition. Rocket Pharmaceuticals' average media sentiment score of 0.36 beat DT Cloud Star Acquisition's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Neutral
DT Cloud Star Acquisition	Neutral

Summary

Rocket Pharmaceuticals beats DT Cloud Star Acquisition on 8 of the 11 factors compared between the two stocks.

Get DT Cloud Star Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTSQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTSQ vs. The Competition

Export

Metric	DT Cloud Star Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$102.36M	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	N/A	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	N/A	15.45	10.46	6.33
Net Income	N/A	-$22.86M	$3.49B	$358.33M
7 Day Performance	1.23%	-1.21%	0.59%	1.12%
1 Month Performance	2.16%	-4.42%	-2.01%	-2.67%
1 Year Performance	N/A	37.81%	18.09%	6.01%

DT Cloud Star Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTSQ DT Cloud Star Acquisition	N/A	$11.58 +0.7%	N/A	+10.6%	$102.36M	N/A	N/A	3	Positive News
RZLT Rezolute	2.3505 of 5 stars	$4.22 +1.2%	$9.38 +122.2%	-53.2%	$401.54M	N/A	N/A	40
LRMR Larimar Therapeutics	3.3827 of 5 stars	$3.92 +1.8%	$11.67 +197.6%	-11.4%	$399.95M	N/A	N/A	30	High Trading Volume
ARCT Arcturus Therapeutics	2.9668 of 5 stars	$14.73 +5.4%	$23.00 +56.1%	-18.3%	$397.35M	$82.03M	N/A	180	News Coverage
EVMN Evommune	3.2516 of 5 stars	$10.57 +0.1%	$33.33 +215.4%	N/A	$383.24M	$13M	N/A	45	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTSQ) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. RZLT, LRMR, ARCT, EVMN, and RCKT

How does DT Cloud Star Acquisition compare to Rezolute?

Summary

How does DT Cloud Star Acquisition compare to Larimar Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Arcturus Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Evommune?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. RZLT, LRMR, ARCT, EVMN, and RCKT

How does DT Cloud Star Acquisition compare to Rezolute?

Does the media prefer RZLT or DTSQ?

Is RZLT or DTSQ more profitable?

Do analysts rate RZLT or DTSQ?

Which has more volatility & risk, RZLT or DTSQ?

Do insiders & institutionals hold more shares of RZLT or DTSQ?

Which has stronger earnings & valuation, RZLT or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Larimar Therapeutics?

Do analysts prefer LRMR or DTSQ?

Do institutionals & insiders have more ownership in LRMR or DTSQ?

Does the media prefer LRMR or DTSQ?

Is LRMR or DTSQ more profitable?

Which has more risk and volatility, LRMR or DTSQ?

Which has higher earnings & valuation, LRMR or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Arcturus Therapeutics?

Does the media prefer ARCT or DTSQ?

Which has better earnings & valuation, ARCT or DTSQ?

Is ARCT or DTSQ more profitable?

Do insiders & institutionals believe in ARCT or DTSQ?

Which has more volatility & risk, ARCT or DTSQ?

Do analysts recommend ARCT or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Evommune?

Which has higher valuation and earnings, DTSQ or EVMN?

Does the media refer more to DTSQ or EVMN?

Is DTSQ or EVMN more profitable?

Do analysts prefer DTSQ or EVMN?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Do institutionals & insiders hold more shares of RCKT or DTSQ?

Is RCKT or DTSQ more profitable?

Do analysts rate RCKT or DTSQ?

Which has more volatility & risk, RCKT or DTSQ?

Which has better earnings and valuation, RCKT or DTSQ?

Does the media prefer RCKT or DTSQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools